The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis

2015 ACR Guideline for the Treatment of Rheumatoid Arthritis

November 30, 2015 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

At the 2015 ACR/ARHP Annual Meeting, the ACR unveiled the 2015 Guideline for the Treatment of Rheumatoid Arthritis.

You Might Also Like
  • 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis Now Available
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
  • New Guideline for the Treatment of Psoriatic Arthritis

The introduction states: “Because there has been rapid accrual of evidence and new therapies, advancement of guideline development methodologies, and the need to broaden the scope of its 2012 RA recommendations, the ACR has developed a new 2015 RA pharmacologic treatment guideline. This guideline addresses six major topics: 1) use of traditional disease-modifying anti-rheumatic drugs (traditional/conventional DMARDs, herein referred to as DMARDs), biologic DMARDs (herein referred to as biologics), and tofacitinib, including tapering and discontinuing medications, and a treat-to-target approach; 2) use of glucocorticoids; 3) use of biologics and DMARDs in high-risk populations (i.e., those with hepatitis, congestive heart failure, malignancy, and serious infections); 4) use of vaccines in patients starting/receiving DMARDs or biologics; 5) screening for tuberculosis (TB) in the context of biologics or tofacitinib; and 6) laboratory monitoring for traditional DMARDs.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

According to the guideline authors, “This RA guideline should serve as a tool for clinicians and patients … for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process, taking into account patients’ values, preferences and comorbidities. These recommendations should not be used to limit or deny access to therapies.”

Jasvinder Singh, MD, MPH, a rheumatologist at the University of Alabama who served as principal investigator for the guideline project, told members of the press, “We could not cover every possible clinical scenario in the guideline.” He also emphasized that the recommendations are not meant to be used for insurance purposes.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The guideline includes 74 recommendations: 23% are strong and 77% are conditional. It covers the use of traditional disease-modifying anti-rheumatic drugs (DMARDs), biologic agents, tofacitinib and glucocorticoids in early (<6 months) and established (≥6 months) RA.

Topping the list of recommendations for both early and established RA is the strong recommendation to, regardless of disease activity level, use a treat-to-target approach rather than a non-targeted approach.

In addition, it provides recommendations on tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For an executive summary of recommendations for patients with early RA, established RA and high-risk comorbidities, go to Supplementary Appendix 5.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis, ACR/AHRP Annual Meeting, Arthritis & Rheumatology, Biologics, disease-modifying antirheumatic drugs

You Might Also Like:
  • 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis Now Available
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
  • New Guideline for the Treatment of Psoriatic Arthritis
  • ACR Seeks Partners for Rheumatoid Arthritis Guideline Project

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)